Signature Diagnostics is dedicated to the discovery, validation and commercial development of novel diagnostic products that predict outcome and drug response in patients with colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and ovarian cancer. Signature believes that patient selection and stratification based on molecular gene signatures will soon become an important component of routine cancer treatment.

 

 

news


homepagecontactdirectionsimpressum